Concurrent Chemoradiotherapy Followed by Adjuvant Cisplatin–Gemcitabine vs Cisplatin–Fluorouracil Chemotherapy for N2–3 Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
Lancet Oncol 2023 Jun 02;[EPub Ahead of Print], LT Liu, H Liu, Y Huang, JH Yang, SY Xie, YY Li, SS Guo, B Qi, XY Li, DP Chen, F Jin, XS Sun, ZC Yang, SL Liu, DH Luo, JB Li, Q Liu, P Wang, L Guo, HY Mo, F Qiu, Q Yang, YJ Liang, GD Jia, DX Wen, JJ Yan, C Zhao, QY Chen, R Sun, LQ Tang, HQ MaiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.